Navigation Links
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Date:11/10/2008

I study is validation of Cell Therapeutics Inc.'s capabilities in acquiring attractive drug candidates, and designing and implementing a successful phase III trial," said James A. Bianco, M.D., CEO of Cell Therapeutics. "These data are consistent with the extensive experience with pixantrone in our phase I and phase II studies and demonstrate the ability to offer patients with advanced, relapsed NHL the potential to obtain a clinically meaningful response like a complete remission, despite having failed multiple other courses of chemotherapy or immuno-chemotherapy."

The EXTEND clinical trial is a phase III single-agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial was conducted at 130 sites in 17 countries. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician. The trial was designed to examine the complete remission (CR) or unconfirmed complete remission (uCR) rate, overall survival (OS) and progression-free survival (PFS). The study received Special Protocol Assessment approval from the U.S. Food and Drug Administration (FDA) in 2004 and pixantrone has received fast track designation for this indication.

CTI intends to further evaluate additional details of the study and will provide complete safety and progression-free survival information comparing treatment assignments which is currently being assembled for analysis.

Cell Therapeutics will be presenting at the Rodman & Renshaw Healthcare Conference on November 11, 2008 at 10:45 am Eastern time and a webcast will be available at http://www.celltherapeutics.com.

About Pixantrone

Pixantrone (BBR 2778), a DNA intercalating antit
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
2. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
3. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
4. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
5. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
6. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
7. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
8. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
9. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
10. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
11. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across ... virus, select Meijer pharmacies in Michigan ... to eligible patients, enabling Meijer pharmacists to administer tests and, ... set by a physician participating in the study. ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
... Calif., Jan. 6, 2011 Genesis ... ), a biotechnology company developing targeted cancer therapies, announces that ... Biotech Showcase™ 2011 conference on Wednesday, January 12, 2011, at ... the Parc 55 Wyndham San Francisco – Union Square. ...
... Jan. 5, 2011 WebMD Health Corp. (Nasdaq: ... million of Convertible Notes due 2018 in a private placement. ... proposed offering an option to purchase up to an additional ... being offered only to qualified institutional buyers pursuant to Rule ...
Cached Medicine Technology:Genesis Biopharma to Present at 2011 Biotech Showcase Conference 2WebMD Announces Proposed Offering of Convertible Notes 2
(Date:4/17/2014)... military personnel who served in Iraq and Afghanistan ... injury (TBI) were compared to military personnel without ... Differences in measures of overall disability, cognitive function, ... are reported in an article in Journal ... Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
(Date:4/17/2014)... of Medicine (BUSM) have discovered that the anti-seizure ... model. The findings, reported in the American ... lead to more effective treatments for alcoholism. , ... leading causes of illness and death in the ... limiting the productivity of workers and necessitating huge ...
(Date:4/17/2014)... has the potential to ward off depression among retirees, ... published online in The Journals of Gerontology, ... In the article " Internet Use and Depression Among ... Analysis ," the authors report that Internet use reduced ... among their study sample. , Late-life depression affects ...
(Date:4/17/2014)... ribbon representing a disease. A pink ribbon is well known ... think of with lung cancer?, Although white has been identified ... black may be the only one they think fits., A ... smokers between the ages of 51 to 79 years old, ... these patients, the emotional toll it can have and how ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... of intestinal stem cells that may hold clues to the ... reported March 30 in the journal Cell , appears ... recent discovery of intestinal stem cells that multiply rapidly ... as a "brake" on cell growth and proliferation. , The ...
... renal cell carcinoma, the second most common kidney cancer subtype, ... after surgery. Those are the key findings of a multi-centre ... of the urology journal BJUI . ... to 15% of kidney cancer patients, the small number of ...
... R.I. Rhode Island Hospital physicians identified ... that required endoscopic or surgical removal. The paper calls attention ... aware of this potential danger. It is published in the ... online in advance of print. David Grand, M.D., a ...
... , WEDNESDAY, March 28 (HealthDay News) -- In ... the popular antidepressant Celexa can cause potentially fatal abnormal ... issued new dosing and use recommendations. Last August, ... than 40 milligrams a day can cause changes in ...
... radiation therapy (IMRT) instead of standard whole breast irradiation ... toxicities, according to a study in Practical Radiation ... journal of the American Society for Radiation Oncology (ASTRO)., ... effective breast cancer treatment that also reduces the incidence ...
... (HealthDay News) -- The common cold appears to increase ... makes them more sensitive, which triggers coughing, wheezing and ... are especially vulnerable to this virus-induced coughing, said the ... are known as transient receptor potential (TRP) receptors. ...
Cached Medicine News:Health News:Newly identified stem cells may hold clues to colon cancer 2Health News:Kidney cancer subtype study finds low recurrence and cancer death rates 2Health News:Rhode Island Hospital study identifies the danger of grill brushes 2Health News:FDA Adds More Warnings to Antidepressant's Label 2Health News:IMRT reduces risk of side effects in breast cancer patients 2Health News:Research Shows How Colds Lead to Coughing, Wheezing 2
Boston Multivision design is manufactured in Boston ES material for early presbyope patients. Boston Multivision lens provides crisp, clear vision at near, intermediate, and far distances and excelle...
Ophthalmic surgery stretcher. Designed for exceptional surgeon access, ideal for either superior or temporal approach....
... Reliance mobile surgical stretcher. M-701 ... of 24 in. to 32 in., ... You may specify a high range, ... A 4 in. pad can be ...
... Visionblue is a staining solution for ... required for performing a safe phaco-emulsification ... lens capsule may result in an ... risk of radial capsule tears and ...
Medicine Products: